Please assess the completion status of the following clinical trial:

Trial Title: Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Type 2 Diabetes~* BMI 27-42~* Specified diet/exercise and/or diabetes medications~Exclusion Criteria:~* BP \> 150/95~* Stroke/MI/unstable cardiovascular disease within 6 months~* Clinically significant renal, hepatic, or psychiatric disease~* Unstable thyroid disease or replacement therapy~* Nephrolithiasis~* Obesity of known genetic or endocrine origin~* Participation in a formal weight loss program or lifestyle intervention~* History of glaucoma~* Pregnancy or breastfeeding~* Alcohol abuse~* Eating disorder~* Excluded medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Phentermine 15mg/topiramate 100mg
- 2 (Type: PLACEBO_COMPARATOR): Matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).